Cargando…
AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles
BACKGROUND: Cervical dystonia (CD), the most common focal dystonia, is a chronic neurological movement disorder characterized by sustained involuntary contractions of the neck muscles, leading to abnormal postures. AbobotulinumtoxinA (aboBoNT-A) was approved in the US initially as a 500 U per 1-mL d...
Autores principales: | Dashtipour, Khashayar, Wietek, Stefan, Rubin, Bruce, Maisonobe, Pascal, Bahroo, Laxman, Trosch, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457764/ https://www.ncbi.nlm.nih.gov/pubmed/32884828 http://dx.doi.org/10.1186/s40734-020-00090-x |
Ejemplares similares
-
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
por: Lew, Mark F., et al.
Publicado: (2021) -
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
por: Patel, Atul T., et al.
Publicado: (2021) -
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
por: Patel, Atul T., et al.
Publicado: (2021) -
Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice
por: Trosch, Richard M., et al.
Publicado: (2020) -
Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm
por: Dashtipour, Khashayar, et al.
Publicado: (2015)